← All candidates
No insider filings on record.
15 filings on record.
IBIOiBio, Inc.
NasdaqCM · Healthcare · $77.49M
$1.21
-1.63% · Sep 11
No insider filings on record.
iBio, Inc. hasn't reported Form 4 activity yet.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 1 move explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IBIO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$77.49M
Float
52.1M
81% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
774.9
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
No insider transactions on file for IBIO yet.
Context
Wall St
$5.53 avg target
+356.6% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 3 quarters beat
Q2 '26−$0.07 act−$0.01
Q4 '25−$0.09 act−$0.02
Q3 '25−$0.11 act−$0.04
Coverage
Could iBio (IBIO) Be an Underrated Obesity Stock?Insider Monkey · 06-12We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn RateSimply Wall St. · 05-15iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600Insider Monkey · 04-24iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”MarketBeat · 04-08
The file stays open
15 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice